Medical/Pharmaceuticals
Dong Bang Co Ltd to Showcase Veterinary Pharmaceuticals at Indo Livestock 2026
SEOUL, South Korea, June 5, 2026 /PRNewswire/ -- Dong Bang Co Ltd, a Korean veterinary pharmaceutical manufacturer, will participate in the "Indo Livestock 2026 Expo & Forum," which will be held in Jakarta, Indonesia, from June 16 to 18, as part of its global market expansion strategy. Founded i...
2026-06-05 13:00
5486
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...
2026-06-05 11:30
5681
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
2026-06-05 10:45
10352
Osara Health Expands Into Survivorship Care, Strengthening Cancer Support Beyond Treatment
The expanded Cancer Coach program introduces new survivorship modules building on the latest outcomes showing a 25:1 ROI and ~66% of participants improved physical and mental health. NEW YORK, June 5, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on providing support...
2026-06-05 06:59
3948
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum
2026-06-05 06:00
4196
Global Ergothioneine Market Poised for Accelerated Growth as Scientific Validation and Synthetic Biology Reshape Industry Dynamics
New Frost & Sullivan White Paper Highlights Emerging Opportunities Across Healthy Aging, Functional Nutrition, Personal Care, and Preventive Healthcare SHANGHAI, June 4, 2026 /PRNewswire/ -- Frost & Sullivan's latest white paper, Global Ergothioneine Industry Current Landscape and Development Tre...
2026-06-04 21:35
5834
Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
* WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. * The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate ...
2026-06-04 20:30
5733
PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational
Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide pilot-scale GMP p...
2026-06-04 20:21
5393
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidi...
2026-06-04 18:58
4841
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
* Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan regi...
2026-06-04 18:32
5754
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-04 16:35
9115
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymp...
2026-06-04 16:19
5674
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
* Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model * Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year * Total Marketplace (MP) Service Revenue Increased by 24.7% Year-over-Year * Fulfillment E...
2026-06-04 16:00
10309
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a significant step f...
2026-06-04 11:39
4998
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent ...
2026-06-04 06:01
6320
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-06-03 12:00
9159
New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles. Results revealing no complications and high satisfaction prove the need to adapt surgical techniques for variations in skin ty...
2026-06-03 10:00
6642
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7...
2026-06-03 08:00
7620
Reach Surgical Receives CE Mark Approval for SOUND REACH™ Swift
- The leading innovative plug-and-play ultrasonic shears with integrated transducer designed for open surgery SINGAPORE, June 3, 2026 /PRNewswire/ -- Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for SOUND REACHTM Swift, ultrasonic shears desig...
2026-06-03 07:00
3272
Early Data Show Highly Selective FGFR2 Inhibitor 3HP-2827 Active in Advanced CCA; Chinese Academy of Sciences' Zhou Jian Comments on Potential for Patients With FGFR2 Alterations
CHICAGO, June 2, 2026 /PRNewswire/ -- At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827. The ongoing study focuses on patients with advanced cholangiocarcinoma (CCA) and other solid tumor...
2026-06-02 21:30
7742
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 260 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9432
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8916
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8559
